Previous Close | 33.52 |
Open | 33.52 |
Bid | 33.27 x 100 |
Ask | 33.45 x 100 |
Day's Range | 32.62 - 33.98 |
52 Week Range | 18.61 - 39.26 |
Volume | |
Avg. Volume | 370,781 |
Market Cap | 1.893B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | 15.65 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for HRMY
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 9:30 a.m. ET.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA) Granted Priority Review for WAKIX in Pediatric Narcolepsy; PDUFA Date of June 21, 2024 Meeting with FDA to Discuss Idiopathic Hypersomnia Development Program Scheduled for March 2024 FDA Granted Orphan Drug Designation to Pitolisant for the Treatment of Prader-Willi Syndrome; On Track to Initiate Pha